PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-314.19%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
7.75%
Operating income growth under 50% of AXSM's 35.57%. Michael Burry would be concerned about deeper cost or sales issues.
-313.81%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-286.19%
Negative EPS growth while AXSM is at 20.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-286.19%
Negative diluted EPS growth while AXSM is at 20.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
6.89%
Share count expansion well above AXSM's 1.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.89%
Diluted share count expanding well above AXSM's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.02%
OCF growth at 50-75% of AXSM's 25.25%. Martin Whitman would question if the firm lags in monetizing sales effectively.
16.84%
FCF growth 50-75% of AXSM's 25.25%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14746.74%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19558.18%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-11613.56%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30946.59%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-34054.52%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-30407.41%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-3646.86%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-832.34%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-628.80%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Asset growth above 1.5x AXSM's 7.23%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-341.43%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
Our R&D shrinks while AXSM invests at 10.62%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
43.14%
SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.